Ventyx Biosciences Reports Clinical Data for its NLRP3

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor ...

We are excited to announce clinical updates from our novel NLRP3 inhibitor portfolio, including topline results from the Phase 1 trial of VTX3232 in healthy ...

Ventyx Biosciences Announces Positive Preclinical Data for CNS ...

... data increase our confidence in the role of NLRP3 ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Reports Clinical Data for its NLRP3

We are excited to announce clinical updates from our novel NLRP3 inhibitor portfolio, including topline results from the Phase 1 trial of VTX3232 in healthy ...

Ventyx Biosciences Reports Third Quarter 2024 Financial Results ...

... NLRP3 in humans with evidence of strong efficacy ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Reports First Quarter 2024 Financial Results ...

We continue to believe that data from our Phase 2 study with our ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences Reports Second Quarter 2024 Financial Results ...

“We are looking forward to advancing our portfolio of NLRP3 inhibitors into three Phase 2 clinical trials in the coming months with clinical ...

Ventyx Biosciences Reports Fourth Quarter and Full Year

Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of ...

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its ...

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 ... clinical trials. The initial ...

News Releases – Ventyx Biosciences, Inc.

March 11, 2024. Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event · Read more.

Ventyx Biosciences Announces $27 Million Strategic Investment ...

Data from both trials are expected in 2025. About ... Our current pipeline includes internally discovered clinical programs targeting NLRP3 ...

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 ...

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event.

Ventyx Biosciences Reports Third Quarter 2023 Financial Results ...

... data for our novel CNS penetrant NLRP3 inhibitor ... Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3 ...

Ventyx Biosciences, Inc.: Investors & News

Our clinical-stage pipeline includes VTX3232, a Phase 2 ready CNS-penetrant inhibitor of the NLRP3 inflammasome, VTX2735, a Phase 2 ready peripheral ...

Ventyx Biosciences Reports Positive Preclinical Results for NLRP3 ...

... its NLRP3 inhibitor VTX3232 in mice with diet-induced obesity (DIO). ... The company's pipeline includes clinical programs targeting NLRP3 ...

Ventyx Biosciences Reports Second Quarter 2023 Financial Results ...

... trial of our CNS-penetrant NLRP3 inhibitor ... Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3 ...

EX-99.1 - SEC.gov

Exhibit 99.1. Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress. Topline Phase 1 data for our ...

Ventyx-Biosciences-Reports-Clinical-Data-for-its ... - Larvol Delta

VTX002 - Ventyx Biosci. Zeposia (ozanimod) - BMS. Velsipity (etrasimod) - Pfizer. http://www.ncbi.nlm.nih.gov/pubmed/39252206. Laurent Peyrin-Biroulet; Sophie ...

Ventyx Biosciences Reports Q3 Financial Results and Pipeline ...

... its investors. Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in ... The company also reported progress in its NLRP3 ...

Ventyx Biosciences Announces Positive Preclinical Data for CNS ...

... medical need, today announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models ...

VTYX - Ventyx Biosciences, Inc. Latest Stock News & Market Updates

Ventyx Biosciences announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor, VTX3232. The study, conducted on diet-induced obesity (DIO) ...